Search

Reset

Status

Medical Condition

Displaying 1 - 1 of 1

Study of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of Epidermal Growth Factor Receptor (EGFR)

Condition: Neurological Disorders / Brain Tumors
Investigator: Andrew Lassman, MD
Status: Closed
This is a two-part research study of an investigational drug called ABBV-321 in subjects with glioblastoma (brain tumor). This study will be conducted in two-parts: 1) Dose Escalation Phase: The purpose of the first part, called a Dose Escalation Phase, is where we will increase the dose of ABBV-321 until we find the highest dose before unmanageable side…
Read More